Pulmonary fibrosis
Conditions
Interventions
Myofascial release group:The 24-week intervention will include eight sessions of myofascial release (MFR). The specific schedule is as follows. Participants will receive one MFR session aimed at activ
and 2) enhancement of thoracic breathing, targeting the intercostal muscles, erector spinae, pectoralis major, lateral fascial line, and diaphragm.
In addition, from week 5 to week 24, participants w
Sponsors
Beijing Sport University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The participant meets one of the following diagnostic criteria: - Diagnosed with idiopathic pulmonary fibrosis (IPF), based on the 2022 Clinical Practice Guideline for Adult Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, determined through a comprehensive assessment of high-resolution computed tomography (HRCT) performed within the past 12 months and, if available, lung histopathology (e.g., surgical lung biopsy or transbronchial lung cryobiopsy); - Diagnosed with progressive pulmonary fibrosis (PPF), based on the same guideline, determined through a comprehensive assessment of pulmonary function tests, HRCT findings, and changes in respiratory symptoms over the past 12 months. 2. The participant has received a stable dose of antifibrotic treatment—nintedanib (>=100 mg twice daily) or pirfenidone (>=400 mg three times daily)—for at least 8 consecutive weeks prior to screening and intends to continue the same therapy during the study period; or has not received antifibrotic therapy due to intolerance or personal refusal. 3. The participant has signed the informed consent form and voluntarily agrees to participate in the study..
Exclusion criteria
Exclusion criteria: 1. Age 70 years; 2. Resting oxygen saturation (SpO2) 90% of predicted value; 6. Diffusing capacity for carbon monoxide (DLCO, Hb-adjusted) >90% of predicted value; 7. History of significant cardiac disease within the past 6 months (e.g., uncontrolled heart failure, acute coronary syndrome, coronary stent implantation, etc.); 8. History of stroke within the past 6 months; 9. Presence of lower extremity peripheral arterial disease or deep/iliac vein thrombosis; 10. Acute exacerbation of IPF or interstitial lung disease (ILD), or serious infection within the past month; 11. Presence of active malignancy or other severe chronic illnesses that significantly affect life expectancy; 12. Severe physical disability, long-term bedridden status, cognitive impairment, or communication disorder resulting in inability to live independently; 13. Inability to complete the 6-minute walk test (6MWT) or diaphragmatic ultrasound; 14. Inability to complete the full intervention and assessment protocol; 15. Any other condition deemed by the investigator to make the participant unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Forced vital capacity; | — |
Secondary
| Measure | Time frame |
|---|---|
| St. George’s Respiratory Questionnaire;Diffusing capacity of the lung for carbon monoxide (% predicted value);Forced vital capacity (% predicted value);Diaphragm ultrasound;six minutes walk test;Global Rating of Change Scale;The Living with Pulmonary Fibrosis questionnaire; | — |
Countries
China
Contacts
Public ContactYan Bing
Beijing Sport University
Outcome results
None listed